Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 8Tumor-Agnostic 3Lymphoid 3Genitourinary 3Dermatologic 3Thoracic 2Gynecologic 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Breast 1

Conditions

Lymphoma 8Lymphoma, Extranodal NK-T-Cell 6Neoplasm Metastasis 3Sarcoma 2Lymphoma, Large B-Cell, Diffuse 2Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lung Neoplasms 1Liver Neoplasms 1Immunoblastic Lymphadenopathy 1Head and Neck Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 5Gemcitabine 5Albumin-Bound Paclitaxel 5Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Bevacizumab 4venetoclax 3spartalizumab 3abemaciclib 3Sirolimus 3Pemetrexed 3Paclitaxel 3Leucovorin 3Ipilimumab 3Fluorouracil 3Doxorubicin 3Cisplatin 3Bortezomib 3130-nm albumin-bound paclitaxel 3manganese chloride 2fludarabine phosphate 2fludarabine 2copanlisib 2Taxes 2Midazolam 2Irinotecan 2Interleukin-2 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasm Metastasis × spartalizumab × Lymphoid × Clear all
NCT05631886 2023-08-28

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Chinese PLA General Hospital

Phase 1 Recruiting
10 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis, Recurrence

NCT03311412 2023-05-30

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Symphogen A/S

Phase 1 Completed
89 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis

NCT03991559 2019-08-28

A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

Chinese PLA General Hospital

Phase 1 Unknown
20 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡